Literature DB >> 3416297

Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.

H S Friedman1, S X Skapek, O M Colvin, G B Elion, M R Blum, P M Savina, J Hilton, S C Schold, J Kurtzberg, D D Bigner.   

Abstract

Melphalan transport, glutathione levels, and glutathione-S-transferase activity were measured in two continuous human medulloblastoma cell lines and transplantable xenografts in athymic nude mice, TE-671 and Daoy. In vitro mean glutathione levels were 10.06 nmol/10(6) cells in TE-671 and 2.96 nmol/10(6) cells in Daoy. In vitro mean glutathione-S-transferase values were 91.52 nmol/min/mg protein in TE-671 and 50.31 nmol/min/mg protein in Daoy. Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy. Melphalan transport was inhibited by both DL-alpha-2-aminobicyclo[2.2.1]heptane-2- carboxylic acid and sodium ion depletion in TE-671 and Daoy cells in vitro, indicating that both systems of amino acid transport are functional in these medulloblastoma lines. In vivo s.c. xenograft glutathione values were lower (7.79 nmol/mg protein) in TE-671 than in Daoy (13.68 nmol/mg protein). The mean plasma concentration in mice given a 10% lethal dose (71.3 mg/m2) of melphalan i.p. was 50.3 microM at 10 min, with the half-life of 29.9 min. At this dose, s.c. xenograft levels were 2- to 3-fold higher in TE-671 than in Daoy tumors for the 3-h period measured. These studies demonstrate transport parameters confirming facilitated transport of melphalan in human medulloblastoma, a mean murine plasma melphalan concentration (following treatment with melphalan) above the in vitro drug dose at which there is a 90% reduction in the number of colonies in comparison to controls for TE-671 and Daoy for 2 h, and glutathione and glutathione-S-transferase levels in the same range previously reported in other melphalan-sensitive and melphalan-resistant human tumors. Future work with spontaneous and acquired melphalan-resistant human medulloblastoma cell lines and xenografts will define the role of these mechanisms in mediating drug resistance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3416297

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.

Authors:  Y J Lidor; K C O'Briant; F J Xu; T C Hamilton; R F Ozols; R C Bast
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

2.  Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.

Authors:  G E Archer; J H Sampson; R E McLendon; A H Friedman; O M Colvin; M Rose; H Sands; W McCullough; H E Fuchs; D D Bigner; H S Friedman
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines.

Authors:  Q Dong; N Bullock; F Ali-Osman; O M Colvin; D D Bigner; H S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.

Authors:  J A Moscow; C A Swanson; K H Cowan
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

5.  Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Authors:  S M Castellino; H S Friedman; G B Elion; E T Ong; S L Marcelli; R Page; D D Bigner; M W Dewhirst
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

6.  Preclinical activity of melflufen (J1) in ovarian cancer.

Authors:  Charlotte Carlier; Sara Strese; Kristina Viktorsson; Ebba Velander; Peter Nygren; Maria Uustalu; Therese Juntti; Rolf Lewensohn; Rolf Larsson; Jack Spira; Elly De Vlieghere; Wim P Ceelen; Joachim Gullbo
Journal:  Oncotarget       Date:  2016-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.